Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Preclinical | NZ | 30 Sep 2021 | |
Crohn Disease | Preclinical | NZ | 30 Sep 2021 |